CASTLE BIOSCIENCES INC 8-K

What Happened

• On February 26, 2026, Castle Biosciences, Inc. (CSTL) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025. The company also made an investor slide presentation available the same day. The press release and slides are attached to the 8-K as Exhibits 99.1 and 99.2.

Key Details

• Date filed: February 26, 2026 (Form 8-K reporting Items 2.02 and 7.01).
• Disclosure: Press release (Ex. 99.1) announcing Q4 and full-year 2025 results; slide presentation (Ex. 99.2) available for investor use.
• Signatory: Report signed by Frank Stokes, Chief Financial Officer, dated February 26, 2026.
• Regulatory note: The materials are furnished under Item 2.02/7.01 and are not deemed “filed” for Section 18 liability or automatically incorporated by reference into other SEC filings.

Why It Matters

• This 8-K signals that Castle has released its latest quarterly and annual financial results and supporting investor materials; investors should review the attached press release and slide deck for revenue, earnings, guidance, and management commentary. Because the items are furnished (not “filed”), they carry the usual limitations on incorporation by reference, but they are the primary immediate sources for updated earnings and operational information.